CTNNB1 and neoplasm: The missense mutation in CTNNB1 encoding β-catenin had the trunk role in the tumorigenesis of HCC and regulated tumor cell proliferation and tumor angiogenesis [69], while molecularly targeted therapy for CTNNB1 had been found to have the potential in treatment of HCC [70], which was suggested as a promising therapy for HCC patients with low prognosis score in this study.